SG11201909353VA - Hbv vaccine - Google Patents
Hbv vaccineInfo
- Publication number
- SG11201909353VA SG11201909353VA SG11201909353VA SG11201909353VA SG 11201909353V A SG11201909353V A SG 11201909353VA SG 11201909353V A SG11201909353V A SG 11201909353VA SG 11201909353V A SG11201909353V A SG 11201909353VA
- Authority
- SG
- Singapore
- Prior art keywords
- hbv
- international
- polymerase
- oxford
- core
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
HBVCPmutS I CMV promote Linker } FA Non-HBV amino acids Pre F2 PreS Core Polymerase (Pmut) PreS1 Surface C A 2 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) WIP0 I PCT IiiimmounnotiolomonoinolommovoimIE (10) International Publication Number WO 2018/189522 Al (51) International Patent Classification: A61K 39/29 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/GB2018/050948 (22) International Filing Date: 10 April 2018 (10.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1705765.4 10 April 2017 (10.04.2017) GB (71) Applicant: OXFORD UNIVERSITY INNOVATION LTD. [GB/GB]; Buxton Court, 3 West Way, Oxford Ox- fordshire OX2 OJB (GB). (72) Inventors: BARNES, Eleanor; c/o Oxford University In- novation Limited, Buxton Court, 3 West Way, Oxford Ox- fordshire OX2 OJB (GB). CHINNAKANNAN, Senthil; c/ o Oxford University Innovation Limited, Buxton Court, 3 West Way, Oxford Oxfordshire OX2 OJB (GB). (74) Agent: BARKER BRETTELL LLP; Medina Chambers, Town Quay, Southampton Hampshire S014 2AQ (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) = (54) Title: HBV VACCINE Linker Figure 4A N I / 4/ Cleavage sites (57) : The invention relates to a multi-HBV immunogen viral vector vaccine comprising: a viral vector comprising an im- munogen expression cassette, wherein the expression of a protein encoded by the expression cassette is arranged to be driven by a pro- moter, wherein the immunogen expression cassette encodes: a) HBV Core; b) a modified HBV polymerase (P mut ), wherein the modi- fication is a mutation to wild-type HBV polymerase to substantially remove polymerase function; c) HBV surface antigen (HbsAg); and d) an intergenic sequence that is arranged to cause expression of at least the HBV surface antigen (HbsAg) as a separate protein from the HBV core and the modified HBV polymerase (P ), wherein the intergenic sequence is downstream (3') of the sequences mut encoding the HBV core and the modified HBV polymerase (P mut ) and upstream (5') of the sequence encoding the HBV surface antigen (HbsAg); and related compositions, vaccination methods and methods of treatment or prophylaxis of HBV infection.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1705765.4A GB201705765D0 (en) | 2017-04-10 | 2017-04-10 | HBV vaccine |
PCT/GB2018/050948 WO2018189522A1 (en) | 2017-04-10 | 2018-04-10 | Hbv vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909353VA true SG11201909353VA (en) | 2019-11-28 |
Family
ID=58744773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909353V SG11201909353VA (en) | 2017-04-10 | 2018-04-10 | Hbv vaccine |
Country Status (13)
Country | Link |
---|---|
US (2) | US20200113998A1 (en) |
EP (1) | EP3609535A1 (en) |
JP (1) | JP7326157B2 (en) |
KR (1) | KR20200024130A (en) |
CN (1) | CN110913899B (en) |
AU (1) | AU2018251241A1 (en) |
CA (1) | CA3059290A1 (en) |
GB (1) | GB201705765D0 (en) |
MX (1) | MX2019012101A (en) |
MY (1) | MY202396A (en) |
PH (1) | PH12019502310A1 (en) |
SG (1) | SG11201909353VA (en) |
WO (1) | WO2018189522A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
EP3934687A1 (en) * | 2019-03-05 | 2022-01-12 | GlaxoSmithKline Biologicals S.A. | Hepatitis b immunisation regimen and compositions |
EP3986456A1 (en) * | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
MA56535A (en) * | 2019-06-20 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | SELF-REPLICATING RNA MOLECULES FOR HEPATITIS B VIRUS (HBV) VACCINES AND USES THEREOF |
BR112022005687A2 (en) | 2019-09-30 | 2022-06-21 | Gilead Sciences Inc | Vaccines against hbv and methods to treat hbv |
WO2021243149A2 (en) * | 2020-05-28 | 2021-12-02 | President And Fellows Of Harvard College | Protein covariance networks reveal interactions important to the emergence of sars coronaviruses as human pathogens |
CN116367854A (en) * | 2020-07-08 | 2023-06-30 | 杨森科学爱尔兰无限公司 | RNA replicon vaccine against HBV |
EP4205762A1 (en) | 2020-10-02 | 2023-07-05 | Osaka University | Improved dna vaccine for sars-cov-2 |
WO2022133230A1 (en) * | 2020-12-18 | 2022-06-23 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
WO2023086961A1 (en) * | 2021-11-12 | 2023-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sars-cov-2 spike fused to a hepatitis b surface antigen |
US20230310591A1 (en) | 2021-12-07 | 2023-10-05 | Vaccitech (Uk) Limited | Vaccine Boost Methods and Compositions |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2526120A1 (en) * | 2003-06-03 | 2005-02-24 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
CN101573449B (en) * | 2006-08-14 | 2013-09-18 | 浦项工大产学协力团 | A DNA vaccine for curing chronic hepatitis b and a method of preparing same |
KR20120052352A (en) * | 2009-08-07 | 2012-05-23 | 트랜스진 에스.에이. | Composition for treating hbv infection |
CA2827150C (en) * | 2011-02-12 | 2018-09-11 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis b infection |
TWI575070B (en) * | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Hbv polymerase mutants |
CN103173492B (en) * | 2013-03-12 | 2014-08-13 | 中国人民解放军白求恩国际和平医院 | Replicative HBV (Hepatitis B Virus) vector carrying foreign gene and recombinant HBV generated after transfection and corresponding preparation method and application |
GB201321384D0 (en) * | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
-
2017
- 2017-04-10 GB GBGB1705765.4A patent/GB201705765D0/en not_active Ceased
-
2018
- 2018-04-10 JP JP2019555196A patent/JP7326157B2/en active Active
- 2018-04-10 KR KR1020197031896A patent/KR20200024130A/en not_active Application Discontinuation
- 2018-04-10 CA CA3059290A patent/CA3059290A1/en active Pending
- 2018-04-10 MY MYPI2019005911A patent/MY202396A/en unknown
- 2018-04-10 US US16/604,221 patent/US20200113998A1/en not_active Abandoned
- 2018-04-10 WO PCT/GB2018/050948 patent/WO2018189522A1/en unknown
- 2018-04-10 CN CN201880028408.6A patent/CN110913899B/en active Active
- 2018-04-10 AU AU2018251241A patent/AU2018251241A1/en active Pending
- 2018-04-10 MX MX2019012101A patent/MX2019012101A/en unknown
- 2018-04-10 SG SG11201909353V patent/SG11201909353VA/en unknown
- 2018-04-10 EP EP18719248.9A patent/EP3609535A1/en active Pending
-
2019
- 2019-10-08 PH PH12019502310A patent/PH12019502310A1/en unknown
-
2023
- 2023-06-06 US US18/206,249 patent/US20240115694A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3609535A1 (en) | 2020-02-19 |
KR20200024130A (en) | 2020-03-06 |
GB201705765D0 (en) | 2017-05-24 |
CN110913899A (en) | 2020-03-24 |
WO2018189522A1 (en) | 2018-10-18 |
AU2018251241A1 (en) | 2019-10-31 |
JP2020516264A (en) | 2020-06-11 |
US20200113998A1 (en) | 2020-04-16 |
PH12019502310A1 (en) | 2020-09-21 |
CN110913899B (en) | 2024-04-19 |
MY202396A (en) | 2024-04-25 |
CA3059290A1 (en) | 2018-10-18 |
MX2019012101A (en) | 2019-12-11 |
JP7326157B2 (en) | 2023-08-15 |
US20240115694A1 (en) | 2024-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909353VA (en) | Hbv vaccine | |
SG11201808709VA (en) | T cell receptors | |
SG11201808750PA (en) | T cell receptors | |
SG11201909572QA (en) | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection | |
SG11201805229YA (en) | Means and methods for treating hbv | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201807912SA (en) | Vaccine against rsv | |
SG11201909265QA (en) | Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to | |
SG11201804496UA (en) | Recombinant zika vaccines | |
SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
SG11201810149VA (en) | Anti hla-g specific antibodies | |
SG11201811603WA (en) | Novel adeno-associated virus capsid proteins | |
SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201906392WA (en) | Nucleoside-modified rna for inducing an immune response against zika virus | |
SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |